pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,791 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT979Endpoints751BioPharma Dive287BioSpace188Fierce Biotech182onclive165globenewswire health73raps66fda recalls
therapy area
allOncology5736Rare Disease1266Cardiology1065Immunology964Hematology952Pulmonology848Vaccines826Psychiatry & CNS698
  • FDA search for new CBER head focused on small group of final candidates
    The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three or four final candidates, according to a person familiar with the matter. The agency ho…
    Endpoints · 3mo ago↗ source
  • Celcuity strengthens case for ASCO-spotlighted breast cancer drug
    The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
    BioPharma Dive · 3mo ago↗ source
  • Supreme Court restores mifepristone access by mail
    The Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court’s stay. The decision Monday came after makers of the pill asked for an immediate response to a ruling ...
← prev
page 103 of 112
next →
43
fda medwatch32
fda press25
Ophthalmology392
Pain344
Endocrinology & Metabolism343
Infectious Disease335
Endpoints · 3mo ago
↗ source
  • Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
    The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to upend one of the main ways abortion is provided across the…
    STAT · 3mo ago↗ source
  • Researchers urge study of paternal deaths, though a new paper finds fatherhood is protective
    A research letter published on Monday in JAMA Pediatrics argues that paternal mortality deserve more attention
    STAT · 3mo ago↗ source
  • Celcuity's breast cancer win; Odyssey plans $205M IPO
    Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year ...
    Endpoints · 3mo ago↗ source
  • STAT+: Pump the brakes on AI, buddy; and deposition deadlock
    It's tough to write nuanced headlines, but a new study on AI in emergency rooms is getting way overhyped.
    STAT · 3mo ago↗ source
  • With $97M, Latus pursues a different kind of Huntington’s gene therapy
    The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
    BioPharma Dive · 3mo ago↗ source
  • Biotech has a new startup model: Small team, big check and Chinese assets
    A new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large checks…
    Endpoints · 3mo ago↗ source
  • UCB to acquire maker of antibody treatments for autoimmune diseases
    A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
    STAT · 3mo ago↗ source
  • What to know about hantavirus, the illness suspected in a cruise ship outbreak
    A rodent-borne illness is suspected of causing an outbreak aboard a cruise ship that has killed three people and sickened others. Here's what to know about hantavirus.
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news
    Two drugmakers asked the U.S. Supreme Court to restore mail-order access to the abortion pill mifepristone, after an appeals court suspended deliveries
    STAT · 3mo ago↗ source
  • Federal court blocks mailing of mifepristone
    Longevity "blue zones," an update on uterine transplant science, and more Morning Rounds health news
    STAT · 3mo ago↗ source
  • Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
    A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...
    Endpoints · 3mo ago↗ source
  • STAT+: Biotech raises $42 million to run Huntington’s disease trial
    Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's disease.
    STAT · 3mo ago↗ source
  • UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
    The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.
    BioPharma Dive · 3mo ago↗ source
  • What is your AI drug repurposing strategy missing?
    Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.
    BioPharma Dive · 3mo ago↗ source
  • Immigration changes are driving foreign researchers to leave the U.S. — or not come to begin with
    Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering leaving early.
    STAT · 3mo ago↗ source
  • Opinion: Are blue zones real? Answering that question is harder than ever
    "Blue zones" as a concept have strayed far and wide from their humble roots, write Shelley Wood and Eric Topol.
    STAT · 3mo ago↗ source
  • Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies
    China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
    STAT · 3mo ago↗ source
  • UCB bets $2B on Candid's T cell engager ambitions
    Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is…
    Endpoints · 3mo ago↗ source
  • Federal appeals court blocks mailing of abortion pill mifepristone
    Mifepristone, involved in most abortions in the U.S., can now be distributed only in person and at clinics.
    STAT · 3mo ago↗ source
  • Opinion: What do medical students think about their education?
    “No one's pulling the pieces together”: a conversation with medical students about preventive care education.
    STAT · 3mo ago↗ source
  • Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical school
    “Unfortunately, the resources don't exist to take every flat-earther to the International Space Station to change their mind,” a STAT reader writes.
    STAT · 3mo ago↗ source
  • Bristol Myers’ pivotal year; Should AI be swinging bigger?; and more
    Welcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman took a close look at a make-or-brea…
    Endpoints · 3mo ago↗ source